Colombotai Bio-B (06990) rose more than 8% to an intraday high of HK$192.8, a record high. As of press release, it rose 7.04% to HK$190, with a turnover of HK$778.87 million.
The Zhitong Finance App learned that Columbotai Bio-B (06990) rose by more than 8%, with an intraday high of HK$192.8, a record high. As of press release, it rose 7.04% to HK$190, with a turnover of HK$778.87 million.
According to the news, Colon Biotech plans to place 3,648,600 shares to no less than six undertakers at a price of HK$150, a discount of about 6.83% from the closing price of HK$161 on May 7, with a net proceeds of approximately HK$540.5 million. The company will also place 4.423,900 shares at the same price of HK$150 per share to the controlling shareholder Colon Pharmaceuticals, with a net proceeds of approximately HK$662 million. Colon Pharmaceuticals will maintain a shareholding ratio of around 54.8% in the company.
In addition, Collumbotai Biotech announced at the beginning of this month that its main product, A400 (EP0031), was approved by the US Food and Drug Administration (FDA) to enter Phase 2 clinical development. A400 is a second-generation selective RET (rearrangement during transfection) inhibitor with broad activity against common RET gene fusions and mutations.